Funding

Sources of Funding, Updated January 2018

ICER’s mission is funded through a diverse combination of sources as grants, contracts and unrestricted gifts; funding is not accepted from manufacturers or private insurers to perform reviews of specific technologies. ICER’s core programs, CTAF, Midwest CEPAC, and New England CEPAC, receive their funding from private foundations.  Since January 2017, ICER has received contributions from the following sources:
  • Bayer
  • Blue Cross Blue Shield of Massachusetts
  • Blue Shield of California Foundation
  • California Health Care Foundation
  • Cantor Fitzgerald
  • Eastern Medicaid Pharmacy Administrators Association
  • Guggenheim Securities
  • Guidepoint
  • Harvard Pilgrim Health Care
  • Laura and John Arnold Foundation
  • Leerink Partners
  • NESCSO/University of Massachusetts
ICER also receives support from pharmaceutical and health insurance companies for the annual ICER Policy Summit, Evidence Dialogue webinars, and other membership activities.  Current members include:
  • Aetna
  • Alnylam Pharmaceuticals
  • America’s Health Insurance Plans (AHIP)
  • Anthem
  • AstraZeneca
  • Blue Shield of California
  • CVS Caremark
  • Editas
  • Express Scripts
  • Genentech
  • GlaxoSmithKline
  • Harvard Pilgrim Health Care
  • Health Care Service Corporation (HCSC)
  • Johnson & Johnson
  • Kaiser Permanente
  • Merck & Co.
  • National Pharmaceutical Council
  • OmedaRx
  • Premera Blue Cross
  • Prime Therapeutics
  • Sanofi
  • Spark Therapeutics
  • United HealthCare